Concepedia

Eugene P. Kadar

EP

15

Publications

2.7K

Citations

12

H-Index

2007

Active since

Affiliations

Pfizer (United States)(Current)

Pfizer (United Kingdom)

Utah State University

Monsanto (United States)

Purdue University West Lafayette

Eugene P. Kadar is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug analysis.

ORCID

Top concepts

Publications per year

2007–2025

15

Publications

15

An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.8K citations · Full text

, , +16

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · Nature Communications · 2021 · 284 citations · Full text

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · 2020 · 158 citations · Full text

Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID‐19 Trial of Nirmatrelvir

Ravi Shankar Prasad Singh, Sima S. Toussi, Frances Hackman et al. · Clinical Pharmacology & Therapeutics · 2022 · 150 citations · Full text

Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans

Heather Eng, Alyssa Dantonio, Eugene P. Kadar et al. · Drug Metabolism and Disposition · 2022 · 111 citations · Full text

Rows per page

1–5 of 15